Abstact:Objective To explore the cytokines led to reduced immune pressure in patients with liver cancer associated with HBV basic core promoter(BCP)double mutation(A1762T,G1764A)strains,and their relationship with liver cancer.Methods Subjects infected with HBV BCP double mutant strains were selected from the Long'an county research cohort as research subjects,according to the principle of nested case-control study.Among them,liver cancer patients were included in the case group,and HBsAg asymptomatic carriers were included in the control group.10 cytokines secreted by immune cells known to be induced by HBV in the sera of the subjects collected in 2004 and 2019,including IL-1β,IL-2,IL-4,TNF-α,IL-6,IL-10,IL-17A,IL-12,IFN-γ,and IL-13,were detected using Flow immunofluorescence.The data were statistically analyzed by Mann-Whitney U test.Results The study subjects include 9 patients with liver cancer(case group)and 10 asymptomatic HBsAg carriers(control group).In 2004,only the expression level of cytokine IL-10 was significantly different between case and control(Z=-2.167,P=0.030).The expression level of IL-10 in case group and control group were(4.718±2.075)pg/mL and(2.899±0.745)pg/mL,respectively.In 2019,the expression levels of cytokines IL-6,IL-10,and IL-12 in the case group were significantly higher than in control group(their P values were 0.041,0.020,and 0.003,respectively).In case group,the expression level of IL-10 in 2019(11.433±7.242)pg/mL was significantly higher than that in 2004(4.718±2.075)pg/mL,and the difference was statistically significant(Z=-2.693,P=0.007).Conclusions Cytokines IL-6,IL-10 and IL-12 are associated with liver cancer in HBV BCP double mutant carriers.The increased expression of cytokine IL-10 is associated with reduced immune pressure in patients with liver cancer associated with HBV BCP double mutation(A1762T,G1764A)strains.
cytokinehepatocelluar carcinoma(HCC)hepatitis B virus(HBV)double mutations(A1762T,G1764A)strainsnested case-control study
NETL
NSTL
万方数据
